Stockscreener 앱 받기
3.25
4.13%
-0.14
시간 외 거래:
3.25
전일 마감가:
$3.39
열려 있는:
$3.38
하루 거래량:
2.27M
Relative Volume:
0.69
시가총액:
$589.47M
수익:
$4.03M
순이익/손실:
$-198.37M
주가수익비율:
-2.5896
EPS:
-1.255
순현금흐름:
$-158.74M
1주 성능:
+2.52%
1개월 성능:
+10.17%
6개월 성능:
-15.14%
1년 성능:
-8.45%
1일 변동 폭
$3.195
$3.40
1주일 범위
$3.02
$3.59
52주 변동 폭
$2.67
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
명칭
Prime Medicine Inc
전화
617-465-0013
주소
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.25 | 587.66M | 4.03M | -198.37M | -158.74M | -1.255 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 개시 | Oppenheimer | Outperform |
| 2025-05-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-05-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-20 | 개시 | H.C. Wainwright | Buy |
| 2024-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-04-22 | 개시 | Chardan Capital Markets | Buy |
| 2024-04-08 | 개시 | TD Cowen | Buy |
| 2024-04-03 | 개시 | Wedbush | Outperform |
| 2024-01-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 개시 | Citigroup | Neutral |
| 2023-10-09 | 개시 | BMO Capital Markets | Outperform |
| 2023-07-31 | 개시 | Guggenheim | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2022-11-14 | 개시 | Goldman | Neutral |
| 2022-11-14 | 개시 | JP Morgan | Overweight |
| 2022-11-14 | 개시 | Jefferies | Buy |
| 2022-11-14 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Prime Medicine (NASDAQ:PRME) Trading Down 6.9%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat
Prime Medicine Company Profile & Introduction - Moomoo
Prime Medicine (NASDAQ:PRME) Shares Gap UpStill a Buy? - MarketBeat
PRIME MEDICINE, INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $9 - Bitget
PRME Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Prime (PRME) Results Breakdown: The Available Earnings Metric Delivers a Beat for the Current Session; Investor Response: Shares Fall 3.79% on the DayConsensus Beat Rate - vinanet.vn
BMO initiates Prime Medicine stock with outperform rating By Investing.com - Investing.com Canada
Alphabet Inc. Takes Position in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine: Soon In The Clinic (NASDAQ:PRME) - Seeking Alpha
Prime Medicine, Inc. Stock 12‑Month Price Target Cut to $6.92, Implies 124% Upside - TradingView
Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright - MarketBeat
Prime Medicine: An Initial Prognosis (NASDAQ:PRME) - Seeking Alpha
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Prime Medicine (NASDAQ:PRME) Trading Up 7.3%Still a Buy? - MarketBeat
Prime Medicine's (PRME) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Weekly Recap: Q2 loss/runway into 2027 and PM647 arbitration win, IND Q3 - TradingView
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Renaissance Technologies LLC Sells 408,120 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Prime Medicine (NASDAQ:PRME) Announces Earnings Results, Meets Estimates - MarketBeat
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Prime Medicine, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Prime Medicine Q2 net loss narrows on lower expenses - TradingView
Prime Medicine, Inc. 2026: Revenue $11.04M, EPS ($0.24) — 10-Q Summary - TradingView
PRME: Regulatory advances and cost reductions position pipeline for key clinical milestones in 2027 - TradingView
FDA milestones and Beam ruling frame outlook for Prime Medicine (NASDAQ: PRME) - stocktitan.net
Prime Medicine reports Q2 2026 net loss $42.1M, cash $108.8M; IND/CTA clearances for PM577a - TradingView
BRIEF-Prime Medicine, Inc. Q2 EPS USD -0.24 - TradingView
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Prime Medicine (PRME) Slides 3.3% as Gene Editing Sector Faces Renewed CautionRSI Overbought Alerts - vinanet.vn
PRME Q2'26 Earnings: revenue estimate is 2.25M USD - TradingView
Redmile Group LLC Takes $5.54 Million Position in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine Inc (PRME) Cash Flow - TradingKey
Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prime Medicine Inc (PRME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prime Medicine Inc (PRME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prime Medicine Market Sentiment - Benzinga España
Prime Medicine Inc (PRME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PRME|Prime Medicine Inc|Price:3.015|Chg%:+0.065 - TradingKey
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Prime Medicine, Inc. (PRME) and Community Health (CYH) - The Globe and Mail
Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Price to earnings forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Prime Medicine Buy Rating Reiterated as Pipeline Advances; $6 Price Target Maintained - TipRanks
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease - The Manila Times
Prime Medicine receives FDA clearance for Wilson disease therapy - Investing.com
Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease - TradingView
Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Singapore
Prime Medicine Inc (PRME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):